BCL2 and follicular lymphoma: This conclusion stemmed primarily from the effects of deregulated bcl-2 expression in follicular lymphoma, which resulted in aberrantly prolonged B-cell survival, increased accumulation of transforming mutations, and accelerated transition to more aggressive and therapy-resistant disease (Hua et al, 1988).